Titania - this was one of the issues raised during yesterday's White House briefing, the possibility of extending Paxlovid treatment from 5 to 10 days being discussed. Manufacturer claims it only affects 2% of patients ...
Full transcript at: https://www.whitehouse.gov/briefing-room/press-briefings/2022/05/18/press-briefing-by-white-house-covid-19-response-team-and-public-health-officials-may-18-2022/
The major difference between this chat room and the SNG subReddit group is that on that board everyone - every single one - treats all other posters with respect. There are no egos out for an airing, no taking pot-shots at the opinion of others and no bragging. The code (if there is one) is the one we should all use in life: 'treat others exactly as you would wish to be treated.'
Although the LSE SNG board does have some great contributors, unfortunately they are usually in the minority.
Islandgirl - one problem is that a treatment which keeps people out of hospital has to be easily and quickly administered to possibly millions of people, ie: a low cost pill. (I keep thinking about the 'SNG needs a fire to fight' comment).
I like to view the drugs landscape as being split into four broad categories:
1. Protection against catching COVID: vaccines, which will continue to evolve as new variants emerge
2. Minimising symptoms and the odds of hospitalisation: low cost, high volume drugs (pills) - this is an increasingly crowded marketplace which SNG (or a version of it - a simple inhaler?) may one day play a role. The SG016 'Home Trial' leg was too small and unsupported/promoted in the UK to produce great results. The US-funded ACTIV-2 Phase 3 global trial may produce positive results which, given the high cost of a hospital stay, may be cost-justified by their health insurance firms. Not in the UK though.
3. Preventing hospitalised patients on oxygen from getting worse, reducing odds of death, reducing their stay and restoring them to full health more effectively: this seems to be our most promising and exciting market, especially as other contenders have been dropping out of trials due to poor efficacy
4. Preventing patients in ICU with severe symptoms from dying: Dexamethasone is filling this role; SNG is not currently being trialled for this late stage.
I konw this is a very crude summary of a subject in which I am certainly not an expert. But as a long-term SNG investor it helps me to keep a sense of persepective and positioning. From all that I have read, a really interesting possibility is that people might be 'profiled' to establish their specific immune response capability prior to contracting an infection, so that the most appropriate treatment and dosage could be rapidly given. Today, we are using a 'one size fits all' approach. Tomorrow, maybe, treatments might be accurately targeted to suit each patient.
Tim
Andybe4 - hopefully the efficacy will be a good deal higher than 25% although I would expect some deaths within the approx. 310 SNG001 arm. This group is bound to sadly include some very vulnerable breathless patients so I would not be suprised to see perhaps 10-15 deaths in the placebo arm (3%-5%) and hopefully no more than 3-5 deaths in those who had received SNG001. I am just being realistic.
Andybe4 - I haven't been back to this board for a long while, preferring the Reddit SNG sub-group for balance, civility and thorough research. I used to think this place was dominated by idiots. After reading your contributions I realise I was spot-on.
Sakura7 - it was such a breath of fresh air to hear a reasoned scientific argument negating the outrageous claims being made for interferon on here and elsewhere.
Like you, I was also involved during the 1970s and 1980s in research, in my case at the University of Bognor with a team led by Professor Wilhelm de Rhampa. I feel so proud that our small group was the first to identify a new substance 'adrenalin' in mice cells and shortly afterwards it began appearing in human cells too.
Whether this new substance had occurred spontaneously due to a warming climate, diet changes or air pollution we were never able to determine, as I imagine your own team had also pondered where this novel protein 'interferon' had managed to infiltrate the human body. In the case of the new 'adrenalin' we found no evidence that its arrival caused any adverse effects on human biology.
But this is now ancient history, the idle musings of a couple of old 'lab coats' but hopefully useful for the investors on here to keep a sense of perspective. I mean, if one can't believe a scientist such as yourself, who can we believe?
On Kansas update: https://www.facebook.com/kuhospital/videos/390637205976498/
What is it that stops a major sector of the medical research community, writing in this respected publication, from evenmentioning the role of interferons in responding to a viral infection, let alone Sng? How many hundreds of papers have there been now? Is it still that WHO report on I.V. interferon's lack of efficacy? Or that they view interferons as being a throwback to the 70's? I really don't understand, even though I'm still convinced.
SeaBoy
Thank you for taking the trouble to write such a comprehensive report for us. I feel quite humbled. Your detailed, balanced analysis shines like a beacon on this board and we should all feel extremely glad that you're here to proceed such insight. I can't begin to imagine what life must be like for you and your colleagues, so thank you.
Tim